Partner’s Bispecific Bizengri Nabs FDA National Priority Nod in Rare Bile Duct Cancer

On Friday, two days after handing Partner Therapeutics a Commissioner’s National Priority Voucher (CNPV), the FDA gave the all-clear to the company’s bispecific antibody Bizengri as a second-line treatment for adults with advanced, unresectable or metastatic cholangiocarcinoma with an NRG1 gene fusion.